Insulin-like growth factors and prostate cancer.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Epidemiologic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.EPIREV.A000796PMID 11588855
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators.

  2001cited by this paper
• Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

  2001cited by this paper
• Insulin-like Growth Factors and Prostate Cancer

  2001cited by this paper
• Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice.

  2000cited by this paper
• Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.

  2000cited by this paper
• Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

  2000cited by this paper
• The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

  2000cited by this paper
• Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy.

  2000cited by this paper
• Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

  2000cited by this paper
• The significance of serum levels of insulin‐like growth factor‐1 in patients with prostate cancer

  2000cited by this paper
• The study of cancer risks in populations.

  2000cited by this paper
• Secular trend in body height and weight of Australian children and adolescents.

  2000cited by this paper
• Hormonal predictors of prostate cancer: a meta-analysis.

  2000cited by this paper
• Lycopene Interferes With Cell Cycle Progression and Insulin-Like Growth Factor I Signaling in Mammary Cancer Cells

  2000cited by this paper
• Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

  2000cited by this paper
• Cancer and insulin-like growth factor-I

  2000cited by this paper
• Growth hormone (GH) replacement therapy: cancer in adults treated with GH.

  2000cited by this paper
• Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.

  2000cited by this paper
• Insulin-like growth factor physiology and cancer risk.

  2000cited by this paper
• Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men

  2000cited by this paper
• Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

  2000cited by this paper
• Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?

  2000cited by this paper
• Insulin-like growth factor-I: a key regulator of human cancer risk?

  1999cited by this paper
• Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development.

  1999cited by this paper
• Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins.

  1999cited by this paper
• Serum insulin‐like growth factor‐1 is not a useful marker of prostate cancer

  1999cited by this paper
• The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

  1999cited by this paper
• Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer.

  1999cited by this paper
• Insulin-like growth factor-binding protein-1 and prostate cancer.

  1999cited by this paper
• Secular trends in male adult height 1904-1996 in relation to place of residence and parent's educational level in Portugal.

  1999cited by this paper
• Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men.

  1999cited by this paper
• Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults.

  1999cited by this paper
• Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3

  1999cited by this paper
• Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins.

  1999cited by this paper
• Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

  1999cited by this paper
• Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.

  1999cited by this paper
• Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.

  1999cited by this paper
• Perplexing polymorphisms: D(i)ps, Sn(i)ps, and trips.

  1999cited by this paper
• Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer.

  1999cited by this paper
• Normal growth and development in the absence of hepatic insulin-like growth factor I.

  1999cited by this paper
• Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection.

  1999cited by this paper
• IGFs and Human Cancer: Implications Regarding the Risk of Growth Hormone Therapy

  1999cited by this paper
• Insulin-like growth factor-I and new opportunities for cancer prevention.

  1998cited by this paper
• Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5.

  1998cited by this paper
• Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.

  1998cited by this paper
• Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

  1998cited by this paper
• Akt-Dependent and -Independent Survival Signaling Pathways Utilized by Insulin-Like Growth Factor I

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability

  1998cited by this paper
• Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.

  1998cited by this paper
• Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089.

  1998cited by this paper
• Study Suggests New Way to Gauge Prostate Cancer Risk

  1998cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Secular changes in the growth of Toronto children during the last century.

  1998cited by this paper
• Mechanisms of Antineoplastic Action of Somatostatin Analogs

  1998cited by this paper
• Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• The IGF-I receptor in cell growth, transformation and apoptosis.

  1997cited by this paper
• Gene expression profiles in normal and cancer cells.

  1997cited by this paper
• Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways*

  1997cited by this paper
• Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate.

  1997cited by this paper
• Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.

  1997cited by this paper
• Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

  1997cited by this paper
• Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation.

  1997cited by this paper
• Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism*

  1997cited by this paper
• Chemoprevention of prostate cancer: The prostate cancer prevention trial

  1997cited by this paper
• Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers.

  1997cited by this paper
• Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells.

  1996cited by this paper
• Insulin-like Growth Factor Binding Protein 3 Mediates Retinoic Acid- and Transforming Growth Factor β2-induced Growth Inhibition in Human Breast Cancer Cells

  1996cited by this paper
• Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3.

  1996cited by this paper
• Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation.

  1996cited by this paper
• Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells (*)

  1996cited by this paper
• The insulin-like growth factor I receptor: a key to tumor growth?

  1995cited by this paper
• Molecular and cellular aspects of the insulin-like growth factor I receptor.

  1995cited by this paper
• Role of cell proliferation in regenerative and neoplastic disease.

  1995cited by this paper
• Insulin-like growth factors and their binding proteins: biological actions.

  1995cited by this paper
• Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

  1995cited by this paper
• Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients.

  1994cited by this paper
• Nutritional regulation of the insulin-like growth factors.

  1994cited by this paper
• Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.

  1994cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

  1994cited by this paper
• The IGF axis in the prostate.

  1994cited by this paper
• The ratio between serum levels of insulin‐like growth factor (IGF)‐I and the IGF binding proteins (IGFBP‐1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients

  1994cited by this paper
• Epidemiologic evidence for the increased cell proliferation model of carcinogenesis.

  1993cited by this paper
• In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen.

  1993cited by this paper
• Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.

  1992cited by this paper
• A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.

  1991cited by this paper
• Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells.

  1991cited by this paper
• Genetic errors, cell proliferation, and carcinogenesis.

  1991cited by this paper
• The Role of Cell Proliferation in Multistage Carcinogenesis

  1991cited by this paper
• Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.

  1990cited by this paper
• Cell proliferation in carcinogenesis.

  1990cited by this paper

• Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities

  2024cites this paper
• Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients

  2022cites this paper
• Treatment-induced ABC-mediated multidrug resistance in PC-3 prostate cancer

  2020cites this paper
• Applied physiology of IGF-I: case reports of gene therapy of malignant tumors especially glioma.

  2018cites this paper
• IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line

  2018cites this paper
• Assessment of the Relationship Between Serum Prostate-Specific Antigen Level and Serum Fasting Glucose, Total Cholesterol and Neutrophil-Lymphocyte Ratio in Men Aged 50-70 Years with Prostate-Specific Antigen Level 0-10 ng/mL without Prostate Cancer Diagnosis

  2018cites this paper
• Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

  2018cites this paper
• Obesity Indices and Serum Total Prostate Specific Antigen among Hausa Ethnic Group of Northern Nigeria; A Community Survey

  2018cites this paper
• Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways

  2017cites this paper
• Molecular Imaging of IGF-1R in Cancer

  2017cites this paper
• Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 Review

  2017cites this paper
• Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1

  2017cites this paper
• Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial

  2017cites this paper
• Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status

  2017cites this paper
• Inhibition of insulin-like growth factor II (IGF-II)-dependent cell growth by multidentate pentamannosyl 6-phosphate-based ligands targeting the mannose 6-phosphate/IGF-II receptor

  2016cites this paper
• Growth hormone and Insulin like growth factor -1 in relation to prostate cancer and benign prostatic hyperplasia

  2016influential citation
• An Insight of Pulses: From Food to Cancer Treatment

  2016cites this paper
• Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer

  2016cites this paper
• Glycemic Index, Glycemic Load, and Cancer Prevention

  2016cites this paper
• THE EFFECT OF ORAL GLUCOSE TOLERANCE TEST ON INSULIN AND SOME RELATED INDICATORS IN ELDERY MALE PATIENTS WITH PROSTATE CANCER AND BENIGN PROSTAT HYPERPLASIA

  2015cites this paper
• Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors

  2015cites this paper
• Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.

  2015cites this paper
• Androgen Responsiveness in the Pathophysiology of Prostate Cancer

  2015cites this paper
• Mechanism of Cancer Chemopreventiors by Tea Polyphenols in TRAMP Mice: InvoSvement of Insulin-Like Growth

  2015cites this paper
• Biomarkers for evaluation of prostate cancer prognosis.

  2015cites this paper
• Relación entre resistencia a la insulina y factorde crecimiento símil insulina tipo 1 (IGF-1)con la hiperplasia prostática benigna

  2015influential citation
• Carbohydrate intake, glycemic index and prostate cancer risk

  2015cites this paper
• MULTILEVEL DEREGULATION OF SURVIVAL MECHANISMS IN NPM-ALK+ T-CELL LYMPHOMA

  2015cites this paper
• Preclinical assessment of the novel compound EL102 in prostate cancer

  2015cites this paper
• Chapter-10 Prostate Cancer

  2014cites this paper
• Role of the Adjacent Stroma Cells in Prostate Cancer Development and Progression: Synergy between TGF-β and IGF Signaling

  2014cites this paper
• Coffee consumption and prostate cancer risk: an updated meta-analysis

  2014cites this paper
• Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice.

  2014cites this paper
• Induced IGF-1 R activation contributes to gefitinib resistance following combined treatment with paclitaxel , cisplatin and gefitinib in A 549 lung cancer cells

  2014cites this paper
• Immunotherapy of Malignant Tumors Using Antisense Anti-IGF-I Approach: Case of Glioblastoma

  2014cites this paper
• Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I)

  2014cites this paper
• Expression levels of insulin-like growth factors 1 and 2 in head and neck squamous cell carcinoma.

  2014cites this paper
• Epidemiological study of prostate cancer (EPICAP): a population-based case–control study in France

  2014cites this paper
• Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

  2014cites this paper
• The Effect of Diet, Exercise and Metformin on the Progression of Prostate Cancer

  2014cites this paper
• The antitumor potential of Interleukin-27 in prostate cancer

  2013cites this paper
• Cixutumumab-associated pancolitis in a patient with prostate cancer.

  2013cites this paper
• Angiogenic and Tissue Remodeling Factors in the Prostate of Elderly Rats Submitted to Hormonal Replacement

  2013cites this paper
• Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.

  2013cites this paper
• Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study.

  2013cites this paper
• Post genome-wide association studies functional characterization of prostate cancer risk loci

  2013influential citation
• Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer

  2013cites this paper
• Influence of Obesity and Related Metabolic Alterations on Colorectal Cancer Risk

  2012cites this paper
• The IGF-I Axis in Prostate Cancer: The Role of Rapid Steroid Actions

  2012cites this paper
• A feasibility study of a home-based exercise intervention for prostate cancer patients on androgen deprivation therapy

  2012cites this paper
• Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

  2012influential citation
• Overcoming Drug Resistance and Treating Advanced Prostate Cancer

  2012cites this paper
• The Interplay between the Androgen Receptor, Soluble Factors and Tumour Microenvironment

  2012cites this paper
• Steroid hormone receptors, matrix metalloproteinases, insulin‐like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men

  2012influential citation
• Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.

  2011influential citation
• The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study.

  2011cites this paper
• TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL ONCOLOGISTS FROM: SWOG Operations Office RE: IND Safety Reports for IMC-A12 MEMORANDUM

  2011cites this paper
• TGFbeta-Dependent ROS Regulates a Local Endocrine Communication Network Between Stromal and Epithelial Cells in the Prostate

  2011cites this paper
• Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort

  2011cites this paper
• Diet and cancer.

  2011cites this paper
• Estudio del valor patogénico de la expresión y ruta de señalización de KIT e IGF1R en Sarcoma de Ewing: ¿nuevas posibles dianas terapeúticas?

  2011cites this paper
• Estrogen receptor alpha is essential for the proliferation of prostatic smooth muscle cells stimulated by 17β‐estradiol and insulin‐like growth factor 1

  2011cites this paper
• Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.

  2011cites this paper
• L’étude du rôle d’ARF1 dans la migration et la prolifération des cellules du cancer du sein

  2011influential citation
• Circulating levels of IGF-I and IGFBP-3 in gastric cancer

  2011cites this paper
• The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression

  2011cites this paper
• La voie ERK1/2 : point d’intégration et de convergence des connexions entre voies de signalisation dans les cellules épithéliales de prostate normale

  2010influential citation
• Kostrelaterade riskfaktorer : En litteraturstudie gällande IGF-1 och ökad risk för prostatacancer

  2010cites this paper
• STUDYING THE EFFECT OF OGX-225, A NOVEL ANTISENSE THERAPY, ON PROSTATE CANCER CELLS

  2010cites this paper
• Leukemia, non-Hodgkin's lymphoma, and Wilms tumor in childhood: the role of birth weight

  2010cites this paper
• Intracrine regulation of androgen receptor in prostate cancer

  2010cites this paper
• FUNCTION OF ANDROGEN RECEPTOR IN PROSTATE CANCER EPITHELIAL MESENCHYMAL TRANSITION AND MICROTUBULE TARGETING

  2010cites this paper
• Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.

  2010cites this paper
• Modulation of Intracellular Signalling Pathways by Carotenoids

  2009cites this paper
• Trends in Prostate Cancer Screening: Canada

  2009cites this paper
• Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

  2009cites this paper
• IGF-I, insulin and prostate cancer.

  2009cites this paper
• Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system.

  2009cites this paper
• Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysis

  2009cites this paper
• Phthoxazolin A inhibits prostate cancer growth by modulating tumor–stromal cell interactions

  2009cites this paper
• Modification of androgen receptor function by IGF-1 signaling implications in the mechanism of refractory prostate carcinoma.

  2009cites this paper
• Implications of insulin‐like growth factor‐I for prostate cancer therapies

  2009cites this paper
• Insulin receptor expression by human prostate cancers

  2009cites this paper
• Apigenin suppresses insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study

  2009cites this paper
• Lycopene Effects Contributing to Prostate Health

  2009cites this paper
• Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.

  2009cites this paper
• Causes and consequences of genomic instability in prostatic carcinogenesis.

  2009influential citation
• Leucinostatin A inhibits prostate cancer growth through reduction of insulin‐like growth factor‐I expression in prostate stromal cells

  2009cites this paper
• Hormones inWellnessand Disease Prevention : Common Practices , Current State of theEvidence , and Questionsfor the Future

  2008cites this paper
• Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF‐1 receptor and androgen dependent growth of LAPC‐4 prostate cancer cells

  2008cites this paper
• Notch-1 and IGF-1 as Survivin Regulatory Pathways in Cancer: A Dissertation

  2008cites this paper
• Liver-derived IGF1 enhances the androgenic response in prostate.

  2008influential citation
• Lycopene in Cancer Prevention and Treatment

  2008cites this paper
• Hormones in wellness and disease prevention: common practices, current state of the evidence, and questions for the future.

  2008cites this paper
• IGF‐I and INS receptor expression in the salivary glands of diabetic Nod mice submitted to long‐term insulin treatment

  2008cites this paper
• Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial

  2008cites this paper
• Role of Hormonal and Other Factors in Human Prostate Cancer

  2008cites this paper
• Dietary terpenoids and prostate cancer chemoprevention.

  2008cites this paper
• Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.

  2008cites this paper
• CLASSIFICATION OF TESTICULAR GERM CELL TUMORS : INSIGHTS FROM IMMUNOHISTOCHEMISTRY

  2008cites this paper